Safer oral immunotherapy with very low-dose introduction for pediatric hen's egg allergy.

ABSTRACT:

Background

Adverse events could be a barrier to implementing oral immunotherapy (OIT) in children with hen's egg (HE) allergy, highlighting the need for safer OIT methods.

Objective

To determine the safety and efficacy of a new OIT method in a single-center, phase II, double-blind, parallel-group, randomized controlled trial.

Methods

Children aged 1 to 18 years with HE allergy whose cumulative tolerated dose (CTD) range was greater than or equal to 0.1 g to less than 10 g in the oral food challenge test were randomly assigned to the experimental therapy (ET) group with a very low starting dose or to the standard therapy (ST) group with a fixed-quantity maintenance dose for OIT. The primary outcome was safety, measured by days on OIT before the first IgE-mediated immed

SUBMITTER: Ishikawa F 

PROVIDER: S-EPMC12396417 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature